Latest Breaking News On - Qu biologics inc - Page 1 : comparemela.com

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly

Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

British columbiaQu biologics incBiologics inc

Qu Biologics and TransBIOTech Awarded $450K Applied Research and Development Grant Funding

BURNABY, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Coun

United kingdomCarole ann huppTransbiotech quebecTed steinerHal gunnSimon sutcliffeCanadian institutes of health researchTechnology centerDivision of infectious diseasesNatural sciencesBc cancer agencyHead of pharmaceutical sciences at transbiotechCommunity innovationHumanities research councilEngineering council of canadaQu biologics inc

Dr Matt Cahill Appointed Chief Operating Officer of Qu Biologics

Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics - read this article along with other careers information, tips and advice on BioSpace

United kingdomHal gunnSimon sutcliffeMatt cahillTed steinerUniversity of torontoUniversity of cambridgeBc cancer agencyDivision of infectious diseasesQu biologics incBritish columbiaBiologics incSite specific immunomodulatorsChief operatingDeep genomicsChief medical officer

Qu Biologics to Receive $6 7 Million in IRAP Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly

Qu Biologics to Receive $6.7 Million in IRAP Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly. Vancouver, BC, October 27, 2022 Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, announced that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

British columbiaHal gunnTed steinerQu biologics incSite specific immunomodulatorsNational research councilCanada industrial research assistance programInfectious diseasesShirin kalyanScientific innovation

Results from Qu Biologics Crohn s Disease RESTORE Trial

VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific.

United kingdomBritish columbiaHal gunnSimon sutcliffeColitis organizationBrian bressler gastrointestinal research instituteBc cancer agencyQu biologics incBiologics incSite specific immunomodulatorsEuropean crohnPrincipal investigatorBrian bresslerGastrointestinal research instituteModerate to severe crohnDisease activity index